PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12476302-5	2002	The review also discusses our findings that show that phosphoserine Bcr by means of a unique structure, binds to the Abl SH2 domain of the Bcr-Abl oncoprotein, and as a result this SH2 binding inhibits the oncogenic effects of the oncoprotein.	Phosphoserine	54-67	BCR activator of RhoGEF and GTPase	Homo sapiens	68-71	
11809685-0	2002	Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.	Phosphoserine	54-67	BCR activator of RhoGEF and GTPase	Homo sapiens	18-21	
11809685-6	2002	Both species were detected by a Bcr phosphoserine 354 sequence-specific antibody.	Phosphoserine	36-49	BCR activator of RhoGEF and GTPase	Homo sapiens	32-35	
11809685-12	2002	This altered phosphoserine form of the Bcr protein selectively binds to the Abl SH2 domain of the oncoprotein, which we propose down-regulates the activity of the Bcr-Abl tyrosine kinase.	Phosphoserine	13-26	BCR activator of RhoGEF and GTPase	Homo sapiens	39-42	
11809685-12	2002	This altered phosphoserine form of the Bcr protein selectively binds to the Abl SH2 domain of the oncoprotein, which we propose down-regulates the activity of the Bcr-Abl tyrosine kinase.	Phosphoserine	13-26	BCR activator of RhoGEF and GTPase	Homo sapiens	163-166	
10405761-5	1999	In contrast with SH2 binding, tyrosine phosphorylation of Bcr reduced its ability to associate with the 14-3-3 protein Bap-1 (Bcr-associated protein-1), a Bcr substrate and member of a family of phosphoserine-binding adaptor proteins.	Phosphoserine	195-208	BCR activator of RhoGEF and GTPase	Homo sapiens	58-61	
10405761-5	1999	In contrast with SH2 binding, tyrosine phosphorylation of Bcr reduced its ability to associate with the 14-3-3 protein Bap-1 (Bcr-associated protein-1), a Bcr substrate and member of a family of phosphoserine-binding adaptor proteins.	Phosphoserine	195-208	BCR activator of RhoGEF and GTPase	Homo sapiens	126-129	
8912843-7	1996	Our findings indicate that the Abl SH2 binding domain of Bcr in the phosphoserine form inhibits the Bcr-Abl oncoprotein but that tyrosine phosphorylation of this domain of Bcr reverses its inhibitory effects on Bcr-Abl.	Phosphoserine	68-81	BCR activator of RhoGEF and GTPase	Homo sapiens	57-60	
8912843-7	1996	Our findings indicate that the Abl SH2 binding domain of Bcr in the phosphoserine form inhibits the Bcr-Abl oncoprotein but that tyrosine phosphorylation of this domain of Bcr reverses its inhibitory effects on Bcr-Abl.	Phosphoserine	68-81	BCR activator of RhoGEF and GTPase	Homo sapiens	100-103